Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an announcement.
CSPC Pharmaceutical Group has received marketing approval from China’s National Medical Products Administration for a new indication of its irinotecan hydrochloride liposome injection, branded as Duoenyi. This approval allows its use in combination with other drugs for the first-line treatment of metastatic pancreatic cancer, marking a significant milestone as the first domestic approval for such treatment. The decision is based on clinical studies showing improved progression-free survival and a favorable safety profile, reinforcing CSPC’s position in the oncology market and potentially benefiting patients with advanced pancreatic cancer.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company is known for its work in oncology and other therapeutic areas, aiming to provide effective treatment options for various medical conditions.
Average Trading Volume: 125,623,507
Technical Sentiment Signal: Buy
Current Market Cap: HK$89.38B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.